Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 4Esophageal Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Pinealoma 1Pancreatic Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Locally Advanced Rectal Adenocarcinoma 1Locally Advanced Cervical Carcinoma 1Liver Neoplasms 1Liver Diseases 1Hematologic Neoplasms 1Gastric Cancer With Liver Metastases 1Endometrial Neoplasms 1

Interventions

Bevacizumab 39atezolizumab 26durvalumab 24Nivolumab 21lenvatinib 20tremelimumab 16Specimen Handling 16Magnetic Resonance Spectroscopy 13sintilimab 11pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Sorafenib 7Immunoglobulin G 7regorafenib 6Disulfides 6Cyclophosphamide 6cabozantinib 5Radiotherapy 5Radiosurgery 5Blood Specimen Collection 5Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Biopsy 4fludarabine 3donafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Immunotherapy × 90 days × Clear all
NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT07594340 2026-05-22

HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)

Sun Yat-sen University

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07062055 2026-05-08

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Tongji Hospital

Phase 1/2 Not yet recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡